Join to View Full Profile
920 Madison AveSte 877Memphis, TN 38103
Phone+1 408-887-9783
Dr. Sekhon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of TennesseeFellowship, Hematology and Medical Oncology, 2022 - 2025
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hospice and Palliative Medicine, 2019 - 2020
San Joaquin General HospitalResidency, Internal Medicine, 2011 - 2014
Manipal College of Medical ScienceClass of 2008
Certifications & Licensure
CA State Medical License 2013 - 2027
FL State Medical License 2021 - 2023
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
Publications & Presentations
PubMed
- 1 citationsWhy do patients revoke hospice in the emergency departmentHenry Zeng, Bhoomika Kamath, Simranjit Sekhon
The American Journal of Emergency Medicine. 2021-09-15 - Culture Eats Strategy for Breakfast: Reflections on Wang (DOI: 10.1089/jpm.2019.0251) Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients in ...Henry Zeng, Simran Sekhon, Vyjeyanthi S. Periyakoil
Journal of Palliative Medicine. 2020-01-01 - 14 citationsIsolated pulmonary valve endocarditis: truth or myth?Siamak M. Seraj, Evanpaul Gill, Simranjit Sekhon
Journal of Community Hospital Internal Medicine Perspectives. 2017-10-18
Abstracts/Posters
- FDA authorized treatment protocol using Deltarex-G as an adjuvant/first line therapy for early-stage, triple-negative metaplastic breast cancerGordon E, Adnan N, Sekhon S, Kim T, Welch S, Reed RA, Hall FL, Chawla SP:, San Antonio Breast Cancer Symposium, San Antonio, Texas, 12/2021
- Preliminary Efficacy from an ongoing Phase 1 dose escalation study of Seclidimistat (SP-2577) in patients with advanced sarcomas and other solid tumorsSant P. Chawla, Victoria S. Chua-Alcala, Jasgit C. Sachdev, David S. Wages, David D. Stenehjem, Daniela Y. Santiesteban, Nadeem Q. Mirza, Simranjit Sekhon, Erlinda M. ..., CTOS, Toronto, Canada, 11/2021
- A Phase 2 study of Talimogene Laherparepvec, Nivolumab, and Trabectedin (TNT) in Advanced SarcomaChawla SP, Kim T, Adnan N, Sekhon S, Chua V, Moradkhani A, Bhuiyan I, Quon D, Gordon EM, CTOS, Toronto, Canada, 11/2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
